表现为重度血小板减少的灾难性抗磷脂抗体综合征1例并文献复习

doi:10.3969/j.issn.1002-1949.2018.07.0018

Chinese Journal of Critical Care Medicine

2018, Vol. 38

Issue (7): 645-648 DOI: 10.3969/j.issn.1002-1949.2018.07.0018

Abstract
Figure/Table
References (18)
Related Citation (4)

［1］Asherson RA. The catastrophic antiphospholipid syndrome［J］. J Rheumatol, 1992, 19(4): 508-512. ［2］Cervera R，Piette JC，Font J，et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients［J］. Arthritis Rheum, 2002, 46(4): 1019-1027. ［3］Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines［J］. Lupus, 2003, 12(7): 530-534. ［4］Cervera R，Rodriguez-Pinto I，Colafrancesco S，et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome［J］. Autoimmun Rev, 2014, 13(7): 699-707. ［5］Asherson RA，Espinosa G，Cervera R，et al. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment［J］. J Clin Rheumatol, 2002, 8(3): 157-165. ［6］Nayfe R，Uthman I，Aoun J，et al. Seronegative antiphospholipid syndrome［J］. Rheumatology (Oxford), 2013, 52(8): 1358-1367. ［7］Bianchi V，Robles R，Alberio L，et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura［J］. Blood, 2002, 100(2): 710-713. ［8］Rodriguez-Pinto I，Espinosa G，Cervera R. Catastrophic antiphospholipid syndrome - 20 years later［J］. Curr Rheumatol Rev, 2013, 9(2): 73-80. ［9］Rodriguez-Pinto I，Espinosa G，Cervera R. Catastrophic APS in the context of other thrombotic microangiopathies［J］. Curr Rheumatol Rep, 2015, 17(1): 482.〖ZK)〗 ［10］Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome［J］. Curr Rheumatol Rep, 2010, 12(1): 70-76. ［11］Weitz JI，Hirsh J，Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy［J］. Chest, 2004, 126(3 Suppl): 265s-286s. ［12］Girardi G，Redecha P，Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation［J］. Nat Med, 2004, 10(11): 1222-1226. ［13］Espinosa G，Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows［J］. Nat Rev Rheumatol, 2015, 11(10): 586-596. ［14］Uthman I，Shamseddine A，Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome［J］. Transfus Apher Sci, 2005, 33(1): 11-17. ［15］Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases［J］. N Engl J Med, 2012, 367(21): 2015-2025. ［16］Bayraktar UD，Erkan D，Bucciarelli S，et al. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus［J］. J Rheumatol, 2007, 34(2): 346-352. ［17］Vora SK，Asherson RA，Erkan D. Catastrophic antiphospholipid syndrome［J］. J Intensive Care Med, 2006, 21(3): 144-159. ［18］Cervera R，Bucciarelli S，Plasin MA，et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry"［J］. J Autoimmun, 2009, 32(3-4): 240-245.